All News
EULAR 2023 Notes from Milan (6.09.2023)
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.
Read Article
Lupus Landmark Study to Accelerate Personalized Lupus Treatments
The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.
Read Article
Allergic Drug-Induced Arthritis (5.19.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
Read Article
Peresolimab's Potential in Rheumatoid Arthritis
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active rheumatoid arthritis (RA).
Read Article
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that Bruton's tyrosine kinase (BTK) and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported, suggesting that BTK inhibitors might be useful in this population.
Read Article
One in Ten has Autoimmune Disease
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
Read Article
Prevalence and Mortality of IgG4-related disease in the USA
A current review of the epidemiology of IgG4-related disease (IgG4-RD) in the USA shows a low prevalence with possibly increasing numbers, owing to increasing awareness of this unique immune-mediated condition.
Read Article
PJP Prophylaxis Needed with Steroids and Rituximab
Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).
Read Article
National Population Insights (4.28.2023)
Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.
Read Article
Antiphospholipid Antibodies With Incident Cardiovascular Events
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur
Read Article
Steroid-Sparing Rituximab in Polymyalgia Rheumatica
BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year.
Read Article
LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/RYmb3QFB1T https://t.co/sn5hwVxwPk
Links:
Atopic Disease Increases Osteoarthritis Risk
Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis.
Read Article
Anti-mesangial autoantibodies in IgA nephropathy
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney.
Read Article
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
Read Article
Itaconate - A Potential New Immunosuppressive
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
Read Article
NSAIDs in Pregnancy (3.3.2023)
Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
Read Article
VEGA - The Efficacy of Combination Biologics in Ulcerative Colitis
A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.
Read Article
Periodontal Mucosal Breaks Trigger RA Disease Activity
Periodontal disease (PD) is more common in rheumatoid arthritis (RA), especially those with anti-citrullinated protein antibodies (ACPAs). RA activity has been linked to the severity of PD and mucosal inflammation.
Read Article